{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024501","form_type":"8-K","ticker":"IRIX","cik":"0001006045","company_name":"IRIDEX CORP","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.192924+00:00","generated_at":"2026-06-21T22:01:32.822546+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"IRIDEX reports record Q3 revenue $14.6M, net loss narrows to $1.8M; maintains FY guidance","bullets":["Total revenue $14.6M, +10% YoY, record Q3; net loss $1.8M ($0.11/share) vs $2.2M loss ($0.14) prior year.","Retina product revenue $8.8M (+13% YoY); Cyclo G6 revenue $3.5M (+10%).","FDA clearance of next-gen Pascal scanning laser system; first shipments in Q4.","FY revenue guidance maintained at $56-58M; probe units expected ~60,000 (down from 61-63k).","Cash $15.9M, used $2.1M in quarter including $0.5M inventory pre-orders."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024501","json":"https://secwatch.observer/filing/0000950170-22-024501.json","markdown":"https://secwatch.observer/filing/0000950170-22-024501.md","text":"https://secwatch.observer/filing/0000950170-22-024501.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006045/000095017022024501/0000950170-22-024501-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006045/000095017022024501/irix-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:01:32.822546+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4646f287f26e001b560a4040edf150cf75b64fa6","claim":"IRIDEX CORP reported fiscal year 2022 results: revenue $56 million to $58 million. Guidance reaffirmed.","evidence_excerpt":"Iridex continues to expect total revenue for fiscal year 2022 to range from $56 million to $58 million, reflecting growth of 4% to 8% over fiscal year 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006045/000095017022024501/0000950170-22-024501-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2022"},{"label":"Revenue","value":"$56 million to $58 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"cc222bde11594dba26a08ba3b5aebcc885bb256f","claim":"IRIDEX CORP reported the third quarter ended October 1, 2022 results: revenue $14.6 million, net income $1.8 million, EPS $0.11 per share.","evidence_excerpt":"the treatment of glaucoma and retinal diseases, today reported financial results for the third quarter ended October 1, 2022. Third Quarter 2022 Highlights • Total revenue of $14.6 million, a record third quarter revenue, and an increase of 10% over the prior year period • Gross Margin was 44.1% compared to 43.6% in the prior year period • Cyclo G6® product family","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006045/000095017022024501/0000950170-22-024501-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended October 1, 2022"},{"label":"Revenue","value":"$14.6 million"},{"label":"Net income","value":"$1.8 million"},{"label":"EPS","value":"$0.11 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}